KRW 100 billion Viread market preoccupied by Chong Kun Dang

Published: 2016-03-08 15:37:17

Updated: 2016-03-08 15:37:17

Chong Kun Dang has took a step forward for commercialization of an incrementally modified drug of Viread(generic name: tenofovir), a chronic hepatitis B treatment.

The Ministry of Food and Drug Safety(MFDS) approved a Phase 3 clinical trial approval of a Viread-modified drug, CKD-390,’ developed by Chong Kun Dang on the last 4^th.

The clinical trial will assess efficacy and safety between CK...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.